LYVE-1 (also termed CRSBP-1), a 120-kDa disulfide-linked dimeric type I membrane glycoprotein, is a specific marker for lymphatic endothelial cells (LECs) and exhibits multiple ligand (hyaluronic acid and growth factors/cytokines) binding activity in mammals. Recent studies indicate that LYVE-1/CRSBP-1 ligands , PDGF-BB, oligopeptides containing the cell-surface retention sequence (CRS) motifs of VEGF-A 165 and PDGF-BB) induce opening of lymphatic intercellular junctions in vitro and in vivo. To determine the function of the ortholog of mammalian LYVE-1 in zebrafish, we cloned it (zLyve-1). The cloned cDNA (zlyve1) encodes a 328-amino-acid type I membrane glycoprotein. The protein and genomic structure evidence supports the notion that the cloned zLyve-1 is the ortholog of LYVE-1 in zebrafish. zLyve-1 expressed in cultured cells by transfection exhibits hyaluronic acid binding activity but lacks the growth factor binding activity seen in mammalian homologs. Knockdown of zLyve-1 levels by embryo microinjection with a specific antisense morpholino oligonucleotide (MO2) in wild-type and Tg(fli1:EGFP)-transgenic zebrafish causes defects in thoracic duct (TD) formation. Such zebrafish injected with MO2 also exhibit impaired TD flow (as determined by intramuscular injection of FITC-dextran). The phenotypes in these zebrafish injected with MO2 are reversed by co-injection with zlyve1cDNA. In situ hybridization reveals that zLyve-1 is expressed in the posterior cardinal vein (PCV). Expression of zLyve-1 at the highest level in the PCV occurs at 3 dpf which coincides with the time for TD formation in zebrafish development. These results suggest that zLyve-1 is required for TD formation. They also suggest that zLyve-1 is distinct from mammalian LYVE-1 in its role in lymphatic function.
Introduction
Cell-surface retention sequence (CRS)-binding protein-1 (CRSBP-1) was identified in cultured transformed cells and plasma membranes purified from liver tissue in 1995 by its ability to bind PDGF-BB, VEGF-A 165 and synthetic oligopeptides containing the CRS motifs of PDGF-BB and VEGF-A 165 [1, 2] . The CRS motifs contain a cluster of basic amino acid residues (Arg, Lys, His). cDNA cloning, sequencing and expression of bovine CRSBP-1 in 2003 [3] revealed that CRSBP-1 is identical to lymphatic vessel endothelial hyaluronic acid (HA) receptor-1 (LYVE-1), which was identified by CD44 homology cloning in 1999 [4] . LYVE-1 has been used as a specific marker for lym-phatic endothelial cells (LECs) and lymphatic vessels in mammals [5] . CRSBP-1/LYVE-1 expressed in cultured cells is a 120-kDa disulfide-linked dimeric type I membrane glycoprotein, and exhibits multiple ligand (hyaluronic acid and growth factors/cytokines) binding activity in mammals [3] . Recent studies indicate that CRSBP-1/LYVE-1 ligands (such as hyaluronic acid, PDGF-BB, VEGF-A 165 and synthetic oligopeptides containing the CRS motifs of VEGF-A 165 and PDGF-BB) induce opening of lymphatic intercellular junctions in vitro and in vivo, resulting in an increase in the transit of fluid, large molecules and cells from the interstitial space into lymphatic vessel lumens (termed interstitial-lymphatic transit) in mice [6] [7] [8] .
We hypothesized that CRSBP-1/LYVE-1 plays an import role in lymphatic function in all vertebrate animals, including zebrafish. To test this hypothesis, our studies aimed at cloning the zebrafish ortholog (zLyve-1) of mammalian LYVE-1 and defining its role in lymphatic vessel formation and function. The lymphatic vasculature has been characterized in zebrafish [9] [10] [11] [12] . Zebrafish possess a lymphatic vascular system that has morphological, molecular and functional characteristics like those found in other vertebrates [9] [10] [11] [12] . It is an excellent animal system in which to investigate how lymphatic vessel formation and function are determined by proteins specifically expressed in LECs. Gene expression knockdown by embryo microinjection with specific antisense morpholino oligonucleotides (MOs) is a simple and effective strategy to define the roles of target genes in the development of lymphatic vessels in zebrafish in a relatively short time (days) [13, 14] . Compared to other vertebrates, the zebrafish offers several other advantages including small size, optical clarity (fluorescent blood and lymphatic vessel structures are easy to see in transgenic Tg(fli1:EGFP) zebrafish) and rapid development (days) of embryos [15] .
In this communication, we show the cloning of zlyve1 cDNA from zebrafish RNA at the 2 -5 dpf stages by RT-PCR. The analyses of genomic and putative protein structures of the identified zLyve-1 suggest that zLyve-1 is the ortholog of mammalian LYVE-1 in zebrafish. We also show that zLyve-1 expressed in cultured cells exhibits hyaluronic acid-binding activity but lacks the growth factor-binding activity seen in mammalian LYVE-1, as determined by cetylpyridinium chloride precipitation and 125 I-labeled VEGF (vascular endothelial cell growth factor) peptide-affinity labeling [3] , respectively. This is consistent with the presence of Link module and absence of the putative growth factor binding domain (the acidicamino-acid-rich region) in zLyve-1 molecule. In addition, we show that zebrafish derived from both wild-type and fluorescent transgenic Tg(fli1:EGFP) embryos microinjected with a specific antisense morpholino oligonucleotide (MO2) exhibit defects in thoracic duct formation and impaired thoracic duct flow (as determined by intramuscular injection of FITC-dextran). These phenotypes can be reversed by co-injection with zlyve1 cDNA. Furthermore, we show that zLyve-1 is expressed in the posterior cardinal vein (PCV), as evidenced by in situ hybridization. Since PCV endothelial cells are known to be precursor cells for LECs forming the thoracic duct (TD), this suggests that zLyve-1 expressed in PCV endothelial cells may play an important role in lymphatic development in zebrafish.
Materials and Methods

Materials
Na 125 I (100 mCi/mL), was purchased from MP Biochemicals (Solon, OH). VEGF peptide (a 25-mer peptide containing the amino acid sequence KKSVRGKGKGQ-KRKRKKSRYKSWSV) was synthesized by C S Bio Co. (Menlo Park, CA). Cetylpyridinium chloride (CPC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (EDAC), Triton X-100, hyaluronic acid (M.W. ~2,000,000) from human umbilical cord (~98% purity), chloramine T and FITC-dextran were obtained from Sigma (St. Louis, MO). Anti-hemagglutinin (HA) epitope antibody was obtained from Cell Signaling (Danvers, MA). pCMV-HA was obtained from Clontech (Mountain View, CA). H1299/bLYVE-1 and H1299/vector cells, which were stably transfected with pCEP-bLYVE-1 cDNA and pCEP vector only, respectively, were prepared as previously described [3] . H1299 cells (human lung carcinoma cells) were transiently transfected with zlyve1 cDNA in the pCMV-HA vector (pCMV-zlyve1-HA) and termed H1299/zlyve1 cells which expressed HA-tagged zLyve-1.
zlyve1 and zlyve1l cDNA Construction
zlyve1 cDNA was amplified from zebrafish RNA at the 2 -5 dpf stages by RT-PCR using the high capacity RNA-to-cDNA Kit TM (Applied Biosystems, Foster City, CA), and KOD FX DNA polymerase (Toyobo Biochemicals, Osaka, Japan). The primer sequences used for PCR were 5'-ATGACACGAGTCTGCATGGG-3' (forward), and 5'-TCATTGTTCTGCAGAGCTACTGTCG-3' (reverse). The amplified cDNA was inserted into the yT & A vector (Yeastern, Taipei, Taiwan) via T-A cloning. The KpnI and XbaI fragment was then sub-cloned into pCMV-HA at KpnI and NotI fill-in sites and termed pCMV-zlyve1-HA. The cDNA (zlyve1l) of zebrafish Lyve-1-like protein was also cloned from zebrafish RNA at the 2 -5 dpf stages using RT-PCR in a similar manner. The CMV promoter is a universal promoter and functional in the zebrafish system.
Multiple Alignments, Phylogenetic Analysis
and Genomic Structural Analysis of zlyve1 (zLyve-1), zlyve1l (zLyve-1-Like) and Other
LYVE-1 Vertebrate Homologs
After cDNA cloning of zLyve-1 and zlyve1-like protein, multiple alignments of these cDNAs with those of other vertebrate orthologs (human, chimpanzee, dog, cow, mouse, rat, chicken and salmon) were performed using the NCBI multiple alignment program. In addition to the multiple alignments, a phylogenetic tree was created using the results from the multiple alignment section of the same program. Genomic structure analysis was also performed using the NCBI sequence viewer for zlyve1, zlyve1l and other vertebrate orthologs.
Transfection
H1299 cells were transiently transfected with pCMVzlyve1-HA and pCMV-HA, using lipofectamine as described [3] and termed H1299/zlyve1 and H1299/vector cells, respectively.
Hyaluronic Acid Binding Activity Assay
The 0.1% Triton X-100 extracts (100 μg protein) of H1299 cells transiently transfected with pCMV-zlyve1-HA (H1299/zlyve1 cells) were incubated with several concentrations of hyaluronic acid (average M.W. ~2,000,000) at room temperature for 1 h. The reaction mixtures were then subjected to CPC precipitation and analyzed by 7.5% SDS-PAGE, followed by Western blot analysis using anti-HA antibody (to immunoprecipitate HAtagged zLyve-1 expressed in H1299/zlyve1 cells). The antigens on the blots were visualized using horseradish peroxidase-conjugated anti-rabbit IgG antibody and the ECL system, as described [3] . The relative intensities of antigen (HA-tagged zLyve-1 which formed complexes with hyaluronic acid) bands on X-ray films were quantified by densitometry.
125 I-VEGF Peptide Binding Assay
125 I-VEGF peptide was prepared using Na 125 I and chloramine T as described [1] [2] [3] 7] . The 125 I-VEGF peptide binding assay in cultured cells was carried out according to our published procedure [1, 3] . Briefly, H1299/ vector, H1299/bovine LYVE-1 (H1299/bLYVE-1) [3] and H1299/zlyve1 cells seeded at the same cell density were incubated with 6 μM 125 I-VEGF peptide with and without 100-fold excess of unlabeled VEGF peptide. After 2.5 h at 4˚C, the specific binding of 125 I-VEGF peptide was estimated by subtracting nonspecific binding, which was determined in the presence of 100-fold excess of unlabeled VEGF peptide, from total binding.
125 I-VEGF Peptide-Affinity Labeling
The 125 I-VEGF peptide-affinity labeling in cultured cells was carried out as described [1] [2] [3] 7] . H1299/vector, H1299/bLYVE-1, and H1299/zlyve1 cells were incubated with 6 μM 125 I-VEGF peptide with and without 100-fold excess of unlabeled VEGF peptide. After 2.5 h at 4˚C, 125 I-VEGF peptide-affinity labeling was carried out by adding EDAC into cells and incubating at 4˚C for an additional 15 min.
125
I-VEGF peptide-affinity labeled cells were subjected to Triton X-100 lysis followed by 7.5% SDS-PAGE and autoradiography.
Husbandry and Maintenance of Zebrafish
We performed zebrafish (Danio rerio) studies according to the US National Institute of Child Health and Human Development Animal Care and Use Committee guidelines for the use of laboratory animals (St. Louis University IACUC office) and those of Academia Sinica, Taiwan, and National Health Research Institutes, Taiwan. Wild-type zebrafish (AB strain) were obtained from natural crosses and subsequent collection of embryos. Embryos were collected by natural spawning, raised in 0.3× Danieau's buffer and then maintained in fish water at 28.5˚C, with feeding twice daily until experiments. The wild-type zebrafish and fluorescent transgenic Tg (fli1: EGFP) zebrafish were also maintained at the facilities (St. Louis University School of Medicine and the Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan and Division of Molecular and Genomic Medicine, National Health Research Institutes, Chunan, Taiwan) in a controlled environment with a 14/10-h light-dark cycle at 28˚C. The fish spawned soon after light onset, and fertilized eggs were collected at the 1-cell stage. The embryos were collected using naturalmating and cultured at 28˚C in Ringer's solution. For rescue experiments, 100 pg of zlyve1 cDNA, which was purified using Qiaquick spin columns (Qiagen), or pCMV-HA vector was co-injected with MO2 or control MO into zebrafish embryos.
Antisense Morpholino Oligonucleotide
RT-PCR Analysis
Total RNAs from 5 embryos at designated stages were isolated by the use of RNA STAT-60 TM reagent (Tel-Test, Inc, USA) or TRIZOL reagent (Invitrogen). First-strand cDNA was synthesized in a 20 μl RT reaction from 1 μg of total RNA by using Super Script III First-Strand synthesis system (Invitrogen), according to the manufacturer's instructions. zlyve1 cDNA fragments of 308 bp and 461 bp were amplified with the following two-pair primers: 5'-G GCCTGTTCATGTCTGGTCTG-3' (forward)/5'-TCTGCACGCCACACCACAACC-3' (reverse) and 5'-ATG ACA CGA GTC TGC ATG GG-3' (forward)/5'-ATC GGC TTT CCG GTT GTC ATT TGG-3' (reverse), respectively. Amplification was carried out in a thermal cycler (2720 thermal cycler, Applied Biosystems, USA) by 30 s denaturation at 94˚C, 30 s annealing at 55˚C and 30 s extension at 72˚C. A total of 35 cycles were carried out. The β-actin and 18 s rRNA RT-PCR products (433 and 241 base pairs, respectively) in total RNAs isolated were used as internal controls.
FITC-Dextran Microinjection
Using a conventional microinjection setup, 5 -7 dpf embryos were embedded in 2% low-melting point agarose, and 2.5 ng/nl FITC-dextran (average M.W. 2,000,000) was injected into the tail muscles of zebrafish embryos. Embryos were then imaged every 2 -3 minutes for evaluation of movement of the large fluorescent molecule. The rate (segments/min) of FITC-dextran fluorescence transit along the thoracic duct was measured between 5 and 20 min after injection of FITC-dextran. The FITC-dextran transit time from injection site to the visible end of the thoracic duct was approximately 20 min.
Whole-Mount in Situ Hybridization
A cDNA fragment of zlyve1 or zlyve1l was cloned into a cloning vector as the DNA template for synthesizing an antisense RNA probe. The T3 polymerase promoter sequence was added to the 3' end of the cDNA by insertion into the 5' end of the reverse primer. Digoxigenin (DIG)-labeled antisense RNA probes were synthesized from the purified PCR products according to the instructions in the MEGAscript Kit (Ambion, Austin, TX) and DIG RNA labeling mix (Roche). Zebrafish larvae at 30 hpf, 3 dpf, 4 dpf and 5 dpf were fixed with 4% paraformaldehyde overnight at 4˚C and dehydrated in methanol at −20˚C. Whole mount in situ hybridization was performed according to the protocol described by the Thisse Lab (https://wiki.zfin.org/display/prot/Thisse+Lab+-+In+Situ +Hybridization+Protocol+-+2010+update) with some modifications. Briefly, zebrafish embryos were rehydrated gradually with PBST (1× PBS, 0.1% Tween 20) and treated with proteinase K for 30 min. After being prehybridized with HYB − (50% formamide, 5× SSC, and 0.1% Tween 20), zebrafish were incubated at 65˚C overnight in HYB + (HYB − plus 50 μg/ml heparin, 500 μg/ml wheat germ tRNA) containing 1 µg/µl of the DIG-labeled antisense RNA probe. They were then washed with 75%, 50% and 25% HYB − /2× SSC for 15 min, 2× SSC for 15 min, and twice with 0.2× SSC for 30 min at 70˚C and transferred gradually to maleic acid buffer (100 mM maleic acid, 150 mM NaCl, 0.1% Tween 20) and blocked in 1× blocking buffer [1% Blocking Reagent (Roche) in maleic acid buffer] for at least 2 h. Zebrafish were then incubated in 1:5000 anti-DIG-AP (Roche) in 1× blocking buffer overnight at 4˚C. After six washes with PBST for 15 min and three washes with alkaline Tris buffer for 5 min, bound antibody was detected using BCIP/NBT (Roche). After staining, the labeled larvae were mounted in 2% methylcellulose. The images were captured using ZEISS ImagerA1 and ZEISS AxioImagerA1 and processed with their associated software.
Statistical Analysis
The values are presented as mean ± S.D. Two-tailed unpaired Student's t-test was used to determine the significance of differences between groups. P < 0.05 was considered significant. Comparisons between the two groups were conducted with the Mann-Whitney test.
Results
Cloning of zlyve1 cDNA
Before cloning the zlyve1 cDNA, we performed a homology search in the zebrafish gene bank using mammalian LYVE-1. We found two genes; one of which was recently identified by Flores et al. [16] and one other, which we named zLyve-1. Because of the protein structure homology found among mammalian LYVE-1, including salmon LYVE-1 (sLYVE-1) and zebrafish Lyve-1 (zLyve-1), we believe that zLyve-1 is the ortholog of mammalian LYVE-1 in zebrafish. We therefore cloned zlyve1 cDNA using the primers generated based on the putative zlyve1 cDNA sequence. The cDNA (zlyve1) of the zebrafish LYVE-1 ortholog (zLyve-1) was cloned from zebrafish RNA at 2 -5 days post fertilization (dpf) using RT-PCR. We obtained the cDNA nucleotide sequence of the cloned zlyve1 (Figure 1(A) ). The zlyve1 cDNA encodes a 328-amino-acid type I membrane glycoprotein containing a 10-amino-acid putative signal peptide, a 187-amino-acid cell-surface domain which includes a 77-amino-acid Link module [17] , a 23-aminoacid transmembrane domain and a 93-amino-acid cytoplasmic domain (Figure 1(B) ). Comparison of the nucleotide and deduced amino acid sequences of zLyve-1 with those of other vertebrate homologs revealed that zLyve-1 has 22% -45% amino acid and nucleotide sequence identity with those of the salmon, chicken, rat, mouse, cow, dog, chimpanzee and human homologs (Figure 1(B) ). zLyve-1 and other known vertebrate LYVE-1 homologs share important protein structural features (Figure 1(C) , panels a, b and c). It is important to note that all vertebrate homologs, including zLyve-1 and sLYVE-1, possess two N-glycosylation sites on both sides of the Link module (Figures 1(B) and (C), panels a, b and c). A zebrafish LYVE-1 ortholog, which was re-
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Open Access CellBio In contrast to all other known vertebrate homologs (e.g., human LYVE-1), zLyve-1 and the other fish homolog, salmon LYVE-1 (sLYVE-1) do not contain an acidic-amino-acid-rich domain (AAAR) which is separated from the Link module and close to the transmembrane domain (Figures 1(B) and (C) , panels a and b vs. panel c). We hypothesize that the AAAR domain orients its acidic side chains of Glu residues toward the basic side chains in the molecule-surface clustered basic amino acid residues of its cognate ligands, including PDGF-BB, VEGF-A 165 , IGFBP-3 and FGF2 [1] [2] [3] 7, 18] . zLyve-1 and sLYVE-1 do not possess this AAAR domain and are expected to lack growth factor/cytokine (with surface clustered basic amino acid residues in the molecule) binding activity.
Genomic Structure and Ligand Binding Activity of zLyve-1
The zlyve1 allele (12.2 kb) resides in chromosome 7 and consists of 6 exons and 5 introns. The genomic structure of the zlyve1 is quite similar to those of other vertebrate homologs (Supplementary Figure S2) . A phylogenetic tree analysis indicates that zLyve-1-like protein (zlyve1l) is evolutionarily distantly related to all known vertebrate LYVE-1 homologs (Supplementary Figure S3) . This supports the notion that zLyve-1-like protein (or zlyve1l) is not the authentic ortholog of LYVE-1 in zebrafish. H1299 cells, which express very little endogenous LYVE-1, have been used to analyze the ligand binding activity of bovine CRSBP-1 (bCRSBP-1 or bLYVE-1) after stable transfection of these cells with its cDNA in pCEP4 vector [3] . To define the ligand (hyaluronic acid) binding activity of zLyve-1, H1299cells were transiently transfected with pCMV-zlyve1-HA and termed H1299/ zlyve1 cells. As shown in Figure 2(A) , zLyve-1 expressed in H1299/zlyve1 cells was identified as a 48-kDa protein by 7.5% SDS-PAGE followed by Western blot analysis using anti-HA (hemagglutinin epitope) antibody (lane 2). The hyaluronic acid-binding activity of zLyve-1 expressed in H1299/zlyve1 cells was determined as described previously [3] by the following procedure: Triton X-100 extracts (100 μg protein) of H1299 cells transfected with expression vector containing zlyve1 cDNA (H1299/zlyve1 cells) or with empty vector (H1299/vector cells) were incubated with several concentrations of hyaluronic acid (M.W. ~2,000,000). The hyaluronicacidzLyve-1 complex in the Triton X-100 extracts was then precipitated by cetylpyridinium chloride (CPC) followed by Western blot analysis using anti-HA (hemagglutinin epitope) antibody as described [3] . The relative amounts of zLyve-1 on the blots, which represented those of zLyve-1-hyaluronic acid complexes precipitated by CPC, were estimated. As shown in Figure 2(B) , hyaluronic acid formed complexes with zLyve-1 in a concentration-dependent manner with a half-maximal concentration of 30 ± 5 μg/ml (n = 4) (panels a and b). This is equivalent to the apparent K d (~15 nM) of hyaluronic acid binding to other vertebrate LYVE-1 homologs [3] . This suggests that zLyve-1 and mammalian LYVE-1 homologs bind hyaluronic acid with the similar affinity.
To determine the growth factor binding activity of zLyve-1, we performed direct binding analysis of I 125 -labeled VEGF peptide (I 125 -VEGF peptide) in H1299 cells transiently transfected with pCMV-zlyve1-HA (termed H1299/zlyve1 cells). VEGF peptide is a 25-mer peptide containing the cell-surface retention sequence (CRS) motif of VEGF-A 165 [1] [2] [3] 7] . We reasoned that, if zLyve-1 possesses I 125 -VEGF peptide binding activity, H1299/zlyve1 cells should exhibit more specific binding (estimated in the presence and absence of 100-fold excess of unlabeled VEGF peptide) of I 125 -VEGF peptide than that found in H1299/vector cells which were H1299 cells stably transfected with vector only [3] . As shown in Figure 2 (C), H1299/zlyve1 cells exhibited less specific binding of I 125 -VEGF peptide than that found in H1299/ vector cells, rather than more specific binding. The apparent I 125 -VEGF peptide specific binding found in these cells (H1299/vector and H1299/zlyve1 cells) appeared to be mediated by other membrane proteins (e.g., low-affinity binding proteins such as proteoglycans) [1] . We speculate that the lower low-affinity specific binding in H1299/zlyve1 cells may be due to lower expression of proteoglycans in these cells. In a positive control experiment, H1299/bLYVE-1 cells (which stably express bovine LYVE-1 (bLYVE-1) that is known to have growth factor binding activity) [3] 2 and lanes 3, 4, respectively) at 4˚C for 2.5 h. 
Requirement of zLyve-1 for Thoracic Duct (TD) Formation
In zebrafish, the TD is the first perfused lymphatic organ and is located between the dorsal aorta (DA) and posterior cardinal vein (PCV). It has been reported that formation of the TD in zebrafish requires the functions of prox1 and vegfc genes [19, 20] . However, the important role of prox1 in TD formation is currently unclear [21] . Like prox1, mammalian LYVE-1 is primarily expressed in LECs and has been used as a specific marker for these cells. zLyve-1 may also be required for lymphatic vessel formation in zebrafish. To test this possibility, we determined the role of zLyve-1 in the development of lymphatic vessels in wild-type zebrafish by knocking down zLyve-1 levels using embryo microinjection with antisense morpholino oligonucleotides (MOs). We designed antisense MOs which targeted 5' UTR (MO1) and the boundaries between exon 1 and intron 1 (MO2) and intron 1 and exon 2 (MO3), and mis-paired MO2, mis-paired MO3 and control MO ( Table 1) . MO2 was the most effective of the MOs used to inhibit translation of zLyve-1 and to generate a TD defect in the embryos which received MO2 injection ( Table 1) . To exclude off-target effects of MO2, we also co-injected MO2 with pCMVzlyve1-HA into zebrafish embryos and examined the zLyve-1 levels and phenotypes of zebrafish embryos. Rescue of the phenotype by cDNA-based overexpression of the targeted transcript has been used to confirm the specificity of MO targeting in zebrafish [22, 23] . As shown in Figure 3(A) (panel a) , injection of MO2 alone at the one-cell stage greatly reduced the level of zLyve-1 in zebrafish embryos, as determined by RT-PCR which yielded a 308-base pair product. MO2 completely knocked down zLyve-1 expression at 1 and 2 dpf (lanes 2 and 4 vs. lanes 1 and 3). Low levels (<20%) of zLyve-1 were observed at 3 -5 dpf (lanes 6, 8 and 10 vs. lanes 5, 7 and 9). It is important to note that, in zebrafish embryos The embryos (survived at 5 dpf) with abnormal phenotypes (pericardial edema and bent tail) were examined for the absence of the TD under a confocal fluorescence microscope. All embryos with a TD defect (no thoracic duct) had pericardialedema.
c Phenol red injection. d Embryos without injection exhibited a 85% survival rate under the experimental conditions. e Survival rate at 5 dpf. not injected with MO2, zLyve-1 was expressed at the highest level at 3 dpf and gradually decreased afterward (Figure 3(A), panel a, lane 5) . Co-injection with pCMVzlyve1-HA reversed MO2-injection-induced knockdown of zLyve-1 levels, as determined by RT-PCR, using a different pair of primers (forward + reverse). This yielded a 461-base pair product (Figure 3(A), panel b, lane 3 vs.  lanes 1, 2) . Injection with MO2 caused edema in the pericardial sac, bent tail and a decreased survival rate (Figure 3(B) , panel b vs. panel a and Table 1 ). Under our experimental conditions, the survival rate of zebrafish at 5 dpf with control MO andd MO1 was 79% -84% ( Table 1 ). The survival rates of zebrafish injected with 8.4 ng MO2 and 8.4 ng MO3 were less (74% -77%). The MO2-injection-induced phenotypes (e.g., edema) and decreased survival rate were reversed by co-injection with pCMVzlyve1-HA (Figure 3(B) , panel c and Table 1 ). These results suggest that MO2-injected embryos may have defects in the formation and/or function of lymphatic vessels, including TD. In zebrafish, loss of the TD has been shown to result in the phenotype of pericardial edema [24] . These results also suggest that the phenotypes of pericardial edema and decreased survival rate in MO2-injected embryos are not due to off-target effects [14] but are specifically caused by the loss of zLyve-1 ecause the phenotypes can be rescued by co-injection b
Open Access CellBio with pCMV-zlyve1-HA but not with pCMV-HA (vector) ( Table 2) .
To test the possibilitythat zLyve-1 is required for lymphatic vessel formation and function, we examined the TDin Tg (fli1:EGFP) zebrafish embryos at 5 dpf after embryo microinjection of Tg (fli1:EGFP) zebrafish with control MO or MO2. The TD is the main conduit of the lymphatic system. It runs through the space between DA and PCV longitudinally, inthe trunk of fluorescent transgenic Tg (fli1:EGFP) zebrafish [10] [11] [12] 25] . Tg (fli1: EGFP) zebrafish, which bear a egfp transgene driven by the zebrafish fli1 promoter Tg (fli1:EGFP), exhibit fluorescence in both blood and lymphatic vascular structures. This is used to examine the formation of blood and lymphatic vessels during development [11, 25] . The TD in Tg (fli1:EGFP) zebrafish derived from embryos microinjected with control MO was analyzed using confocal fluorescence microscopy and was found to be present and not altered (Figure 3(C1) , panels i and ii). It is not different from that seen in Tg (fli1:EGFP) zebrafish de- The embryos with abnormal phenotypes (pericardial edema and bent tail) were examined for the absence of the TD under a confocal fluorence microscope. All embryo with a TD defect (no TD) had pericardial edema.
c Survival rate at 5 dpf.
rived from embryos without injection. Injection with MO2 caused defects in TD formation but had no significant effects on the formation of the blood vascular system (e.g., DA, PCV and intersegmental blood vessels) in this animal. As shown in Figure 3 (C) (panels iii and iv), in embryos injected with MO2, because of the loss of TD and absence of detectable fluorescent cells (e.g., parachordal lymphangioblasts) [12, 25] , the area in the horizontal midline had no fluorescence (as indicated by *). This suggests that embryos injected with MO2 do not develop the TD. We hypothesize that knockdown of zLyve-1 levels by the MO2 injection in the PCV causes the defects in secondary lymphangiogenic sprouts from PCV that give rise to precursors (parachordal lymphangioblasts) of LECs forming the TD [11, 25] . As observed with the phenotype of pericardial edema, the TD defect phenotype in zebrafish derived from embryos injected with MO2 was reversed by embryo co-injection with pCMV-zlyve1-HA (Figure 3(C1) , panels v and vi and Table 2 ). To determine the effect of MO2 injection on lymphatic function, we injected FITC-dextran intramuscularly into wild-type zebrafish derived from embryos injected with MO2 ± pCMV-zlyve1-HA or control MO. We then monitored the 20-min transit of the FITC-dextran along the TD in the trunk from the injection site toward the head in these animals. The FITC-dextran transit time from the injection site to the visible end of the TD was approximately 20 min. As shown in Figure S4(b) ). The ~2 segments were the maximal traveling distance (in >20 min) of FITC-dextran fluorescence. This supports our observation that defective TD formation is caused by injection with MO2 (Figure 3(C1) , panels iii and iv). To rule out the possibility of "off-target" effects of MO2, we co-injected zebrafish embryos with MO2 and pCMVzlyve1-HA or pCMV-HA (vector). The FITC-dextran transit alteration phenotype in zebrafish derived from embryos injected with MO2 was reversed by embryo co-injection with pCMV-zlyve1-HA but not with pCMV-HA. The speed of FITC-dextran transit in zebrafish co-injected with MO2 and pCMV-zlyve1-HA was estimated to be 0.54 ± 0.16 segment/min (mean ± S.D., n = 6) which is almost identical with that obtained from embryos injected with a control MO (Figure 3(C2) , panel a: i, iii, v and panel b). These results indicate that zLyve-1 is required for TD formation.
zLyve-1 Is Highly Expressed in the Posterior Cardinal Vein (PCV)
The finding that zLyve-1 is required for TD formation in zebrafish raises the question of why LYVE-1 is not required for lymphatic development in mammalian species. Null-mutation of LYVE-1 has been shown not to affect lymphatic development in mice [26, 27] , although LYVE-1-null mice exhibit altered morphology and function of lymphatic capillary vessels [6, 7] . In zebrafish, the TD is known to arise from parachordal lymphangioblasts, which are derived from secondary lymphangiogenic sprouts from PCV [11, 25] . A simple possibility is that zLyve-1 is highly expressed in PCV endothelial cells. zLyve-1 may be required for the activation of these cells to become LEC precursors (parachordal lymphangioblasts), which form TD endothelial cells, in zebrafish lymphatic development. To test this possibility, we performed in situ hybridization of zLyve-1 (Figure 4(A) ) and zLyve-1-like protein (Figure 4(B) ) in zebrafish larvae at 30 hpf (hours post fertilization), 3 dpf, 4 dpf and 5 dpf. As shown in Figures 4(A) and (B) , zLyve-1 and zLyve-1-like protein were expressed in the PCV in zebrafish embryosat 30 hpf (panels a, b, c, and d), 3 dpf (panels e, f, g and h), 4 dpf (panels i, j, k and l) and 5 dpf (panels m, n, o and p). At 30 hpf prior to venous sprouting (which would be 36 hpf) [25] , zLyve-1 and zLyve-1 like protein were expressed in the PCV from the caudal to the anterior parts (panels a to d). This suggests potential involvement of zLyve-1 and zLyve-1-like protein in venous sprouting and/or subsequent events. However, at 3 dpf, zLyve-1 was expressed at the highest level in the PCV (panels e and f). This result is consistent with that obtained from RT-PCR analysis (Figure 2(A) , lane 5). In contrast, zLyve-1-like protein was expressed at the highest level in PCVat 30 hpf or earlier than 3 dpf (panels c and d). This indicates that the temporal expression profiles of zLyve-1 and zLyve-1-like protein in PCV are dif-leads to cellular activation of PCV endothelial cells to become LEC precursors (parachordal lymphangioblasts) after interaction with hyaluronic acid or unknown ligands. This hypothesis is based on our recent finding that mammalian LYVE-1 mediates signaling via its partner PDGF β-type receptor after interaction with its ligands, including hyaluronic acid [7] . Open Access CellBio 00:00:13:27 00:00:14:01
